This is used in conjugation with antibodies targeting CD33 (gemtuzumab ozogamicin/Mylotarg) in AML, or CD22 (inotuzumab ozogamicin) in B-cell acute lymphoblastic leukemia (ALL). The gene discussed is CD33; the disease is acute lymphoblastic leukemia.